B. coagulans

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the provided abstracts, Bacillus coagulans (also referred to as Weizmannia coagulans) is most frequently studied in the context of gastrointestinal health and as a functional-food probiotic, with emphasis on its spore-forming biology (acid tolerance, survival through the stomach, germination in the intestine) and its use alone or in synbiotic formulations (with prebiotic fibers). A substantial portion of the evidence base represented here comes from animal agriculture models—particularly broiler chickens—where outcomes include growth performance, gut barrier integrity, pathogen control (e.g., Salmonella enteritidis), antioxidant capacity, and immune markers. Human clinical evidence is present but comparatively limited in scope within these abstracts, exemplified by a randomized, double-blind, placebo-controlled pilot trial in functional dyspepsia using a spore-forming probiotic combination that included B. coagulans.

The strongest support in this set of studies is for (i) biological plausibility and functional robustness of B. coagulans as a probiotic (spore survival and intestinal activity), and (ii) measurable benefits on gut health–related endpoints in controlled animal studies, including improved intestinal morphology/barrier-associated measures, shifts toward beneficial taxa (e.g., increased Lactobacilli/Bifidobacterium), reduced pathogen burden, and modulation of immune/inflammatory readouts. In humans, the most direct efficacy signal described is symptom improvement in functional dyspepsia in a small exploratory RCT of a B. coagulans-containing product, with a safety profile similar to placebo over the study period. Additional proposed benefits (e.g., improved protein digestion/absorption with strain GBI-30, 6086; broader immune modulation; potential roles in inflammatory bowel disease/ulcerative colitis via synbiotics) are supported primarily by mechanistic rationale and early-stage or non-human evidence in the abstracts provided.

Key gaps include the need for larger, well-powered, strain-specific human randomized trials that isolate B. coagulans effects (especially when used in multi-strain products), use standardized clinical endpoints, and assess durability of benefit after discontinuation. More research is also needed to clarify dose–response relationships, comparative effectiveness versus established probiotics, and mechanisms linking microbial changes to clinical outcomes (including barrier function and immune modulation) in humans. Finally, several areas appear preliminary within this set—such as applications in ulcerative colitis/synbiotics and mitigation of toxic exposures (e.g., heavy metals like copper)—and would benefit from rigorous translational studies that connect preclinical findings to clinically meaningful endpoints and safety in relevant patient populations.

1. What conditions has B. coagulans been studied for?

  • Functional dyspepsia (FD): Studied in adults meeting Rome IV criteria in a randomized, double-blind, placebo-controlled pilot trial using a spore-forming probiotic combination that included Bacillus coagulans MY01 (with B. subtilis MY02).

  • Digestive function and nutrient utilization (protein digestion/absorption): A review focused on B. coagulans GBI-30, 6086 for supporting protein digestion and absorption when co-administered with protein.

  • Intestinal dysbiosis-related conditions (as adjuvant therapy): A scoping review reported Weizmannia coagulans (formerly B. coagulans) as among the most commonly used probiotics in contexts where dysbiosis is implicated, including antibiotic-associated diarrhea and irritable bowel syndrome (IBS) (reported as common use, not necessarily proof of efficacy for each condition).

  • Ulcerative colitis (UC): Mentioned in the context of synbiotics and the rationale for B. coagulans as a potential probiotic for intestinal inflammatory disease; the abstract provided is incomplete but indicates investigation in UC models/interventions.

  • Animal health / veterinary indications (broilers):

    • Growth performance, antioxidant capacity, immunity, and gut health as an alternative to antibiotics (broiler feeding study; details truncated).

    • Necrotic enteritis (NE) in poultry as an antibiotic alternative (abstract truncated).

    • Salmonella enteritidis challenge in broilers: evaluated for protection against intestinal inflammation, barrier dysfunction, and pathogen colonization.

  • Toxicant/heavy metal stress models: A zebrafish larvae screening model explored microbes that may alleviate copper (CuSO4) toxicity; evidence for copper toxicity mitigation by probiotics was described as limited.

  • In vitro cancer research (not probiotic supplementation per se): B. coagulans supernatant was used to generate copper oxide nanoparticles tested against breast cancer cell lines (MCF-7, SKBR3).

  • Food/feed processing detoxification: Solid-state fermentation of cottonseed meal to reduce free gossypol (a feed toxin/anti-nutritional factor).

  • Safety assessment: Safety of a newly isolated strain (JBI-YZ6.3) evaluated via genomic and phenotypic analyses (abstract truncated).

2. Does it work in treating those conditions? Summarize the evidence.

  • Functional dyspepsia (human RCT evidence; combination product):

    • In a single-centre randomized, double-blind, placebo-controlled pilot trial (8 weeks), the probiotic arm (B. coagulans MY01 + B. subtilis MY02) had a higher proportion of clinical responders than placebo: 48% (12/25) vs 20% (6/30), relative risk 1.95 (95% CI 1.07–4.11), p=0.028.

    • Limitation: this was an exploratory pilot study and used a two-strain combination, so the specific contribution of B. coagulans alone cannot be isolated from the abstract.

  • Protein digestion/absorption (supportive evidence summarized in a review):

    • The review states B. coagulans GBI-30, 6086 survives gastric acidity, germinates in the intestine, and “has been shown” to aid digestion of carbohydrates and proteins, with co-administration reported to increase protein absorption and maximize benefits of protein supplementation.

    • Limitation: the abstract is a review and does not provide specific trial designs, effect sizes, or endpoints in the excerpt provided.

  • Dysbiosis-associated conditions (evidence of use, not necessarily efficacy):

    • A scoping review reports probiotics are commonly used as co-adjuvant treatments for antibiotic-associated diarrhea, IBS, and childhood allergic diseases, and lists Weizmannia coagulans among the most commonly used strains.

    • Limitation: this is not direct efficacy evidence for B. coagulans in each condition; it summarizes frequency of reporting/usage and broad associations with dysbiosis.

  • Salmonella enteritidis challenge (animal evidence):

    • In broilers, dietary B. coagulans (400 mg/kg) was associated with improved growth metrics during a post-challenge period (e.g., increased body weight gain and gain:feed from day 15–21), increased beneficial bacteria (cecal Lactobacilli and Bifidobacterium), improved gut morphology (higher villous height:crypt ratio; reduced crypt depth), increased goblet cells, and reduced cecal E. coli and Salmonella levels at multiple timepoints.

    • Limitation: animal outcomes may not translate to humans; dosing and strain specifics for human supplements may differ.

  • Necrotic enteritis / antibiotic alternative in poultry:

    • Abstracts indicate investigation and suggest benefit (e.g., “NE-induced reduction in body weight gain was relieved”), but key details are truncated, so strength of evidence cannot be fully assessed from the provided text.

  • Ulcerative colitis (UC):

    • The abstract indicates evaluation of synbiotic/probiotic approaches involving B. coagulans for UC-related inflammation and barrier/microbiota dysfunction, but results are not provided in the excerpt.

    • Conclusion from provided text: insufficient information here to judge efficacy in UC.

  • Copper toxicity mitigation:

    • The zebrafish larvae screening model suggests exploration of microbes that may help with CuSO4 toxicity, but the abstract explicitly notes evidence for relieving copper-induced toxicity by probiotics is still limited.

  • In vitro breast cancer nanoparticle study:

    • BC-derived supernatant was used to synthesize CuO nanoparticles that showed cytotoxic/apoptotic effects in breast cancer cell lines and less adverse effects on normal cells in vitro.

    • Limitation: this is not clinical evidence of cancer prevention or treatment with oral B. coagulans; it is a laboratory nanomaterials study.

3. What health benefits does it have?

  • GI symptom improvement (functional dyspepsia): In a pilot RCT, a spore-forming probiotic regimen including B. coagulans improved responder rates vs placebo over 8 weeks.

  • Digestive support and nutrient utilization: A review describes B. coagulans GBI-30, 6086 as acid-resistant (spore-forming), able to germinate in the intestine, and associated with improved digestion of carbohydrates/proteins and increased protein absorption when taken with protein.

  • Immune and microbiome-related effects (suggestive): The FD trial reported “potentially beneficial immune and microbial changes” (mechanistic signals), though specific biomarkers are not detailed in the excerpt.

  • Gut barrier and pathogen resistance (animal evidence): In Salmonella-challenged broilers, supplementation increased goblet cells and improved villus/crypt measures, shifted microbiota toward more Lactobacilli/Bifidobacterium, and reduced cecal pathogen loads.

  • Potential role in synbiotic strategies for inflammatory bowel disease: The UC abstract frames B. coagulans as a candidate due to sporulation and lactic acid production, but benefits cannot be confirmed from the incomplete results provided.

  • Industrial/food applications with indirect health relevance: Fermentation with B. coagulans reduced free gossypol in cottonseed meal by ~81.8% and increased crude protein content, improving feed safety/nutritional value (primarily relevant to animal feed/food processing rather than direct human supplementation).

4. Does it have any downsides or side effects?

  • Human tolerability (FD pilot RCT; combination product):

    • Adverse events were similar between probiotics and placebo: 16% (5/32) vs 33% (12/36) in the blinded phase.

    • Two serious adverse events during an open-label phase (appendicitis and syncope) were assessed as unlikely related to the study product.

    • Limitation: small sample size and combination of two Bacillus species; may not generalize to other strains/doses or higher-risk populations.

  • Strain-specific safety considerations:

    • A separate abstract describes safety evaluation of a newly isolated strain (JBI-YZ6.3) using genomic and phenotypic approaches (details truncated), highlighting that safety is assessed at the strain level (e.g., taxonomy confirmation, antibiotic susceptibility, genomic screening).

  • Evidence gaps: The provided abstracts do not report common probiotic cautions (e.g., rare infections in severely immunocompromised individuals) for B. coagulans specifically; absence of mention here is not proof of absence.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (i.e., benefits/harms that differ by human genetic variants) for B. coagulans. The functional dyspepsia RCT and the review/mechanistic discussions mention immune and microbial changes but do not describe genotype-stratified responses.

  • Conclusion based on these abstracts: No evidence here that B. coagulans is specifically beneficial or harmful for particular genetic variations.

  • Important limitation: Lack of pharmacogenomic reporting is common in probiotic trials; effects may still vary by host genetics, baseline microbiome, diet, and medication use (e.g., proton-pump inhibitor status was used for stratification in the FD trial, but that is not genetics).

References

  1. Probiotics, prebiotics and synbiotics- a review.
    Kavita R Pandey, Suresh R Naik, Babu V Vakil (2015) - Journal of food science and technology
  2. Bacillus strains as human probiotics: characterization, safety, microbiome, and probiotic carrier.
    Na-Kyoung Lee, Won-Suck Kim, Hyun-Dong Paik (2019) - Food science and biotechnology
  3. Potential Use of
    Gözde Konuray, Zerrin Erginkaya (2018) - Foods (Basel, Switzerland)
  4. Probiotic Bacillus coagulans GBI-30, 6086 Improves Protein Absorption and Utilization.
    Ralf Jäger, Martin Purpura, Sean Farmer, Howard A Cash, David Keller (2018) - Probiotics and antimicrobial proteins
  5. In vitro safety and functional characterization of the novel Bacillus coagulans strain CGI314.
    Shahneela Mazhar, Annie Simon, Ekaterina Khokhlova, Joan Colom, Natasha Leeuwendaal, John Deaton, Kieran Rea (2023) - Frontiers in microbiology
  6. Effects of Bacillus Coagulans on growth performance, antioxidant capacity, immunity function, and gut health in broilers.
    Bing Zhang, Haoran Zhang, Yang Yu, Ruiqiang Zhang, Yanping Wu, Min Yue, Caimei Yang (2021) - Poultry science
  7. Effects of
    Yuanyuan Wu, Yujing Shao, Bochen Song, Wenrui Zhen, Zhong Wang, Yuming Guo, Muhammad Suhaib Shahid, Wei Nie (2018) - Journal of animal science and biotechnology
  8. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial.
    Lucas Wauters, Helena Slaets, Kim De Paepe, Matthias Ceulemans, Suzan Wetzels, Karlien Geboers, Joran Toth, Wannes Thys, Raf Dybajlo, Daan Walgraeve, Erik Biessen, Kristin Verbeke, Jan Tack, Tom Van de Wiele, Niels Hellings, Tim Vanuytsel (2021) - The lancet. Gastroenterology & hepatology
  9. Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review.
    Ailim Margarita Carías Domínguez, Dimas de Jesús Rosa Salazar, Juan Pablo Stefanolo, Maria Claudia Cruz Serrano, Isabel Cristina Casas, Julio Ricardo Zuluaga Peña (2025) - Probiotics and antimicrobial proteins
  10. Bacillus coagulans in Combination with Chitooligosaccharides Regulates Gut Microbiota and Ameliorates the DSS-Induced Colitis in Mice.
    Zhenzhen Liu, Ziyang Jiang, Zhenting Zhang, Tong Liu, Yurong Fan, Tao Liu, Nan Peng (2022) - Microbiology spectrum
  11. Effect of dietary Bacillus coagulans supplementation on growth performance and immune responses of broiler chickens challenged by Salmonella enteritidis.
    Wenrui Zhen, Yujing Shao, Xiuyan Gong, Yuanyuan Wu, Yanqiang Geng, Zhong Wang, Yuming Guo (2018) - Poultry science
  12. Alleviative effects of a novel strain Bacillus coagulans XY2 on copper-induced toxicity in zebrafish larvae.
    Fang Ai, Xuedi Huang, Yalan Wu, Chen Ji, Yufang Gao, Ting Yu, Fujie Yan (2023) - Journal of environmental sciences (China)
  13. Biogenic copper oxide nanoparticles from Bacillus coagulans induced reactive oxygen species generation and apoptotic and anti-metastatic activities in breast cancer cells.
    Masoumeh Dolati, Farzaneh Tafvizi, Masoud Salehipour, Tahereh Komeili Movahed, Parvaneh Jafari (2023) - Scientific reports
  14. Effective gossypol removal from cottonseed meal through optimized solid-state fermentation by Bacillus coagulans.
    Zhenting Zhang, Danlu Yang, Ling Liu, Zhangbing Chang, Nan Peng (2022) - Microbial cell factories
  15. Genomic and Phenotypic Safety Assessment of Probiotic Bacillus coagulans Strain JBI-YZ6.3.
    Yongmei Zhang, Tom J Overbeck, Victoria L Palmer Skebba, Neil N Gandhi (2025) - Probiotics and antimicrobial proteins
  16. Bacillus coagulansand its applications in medicine
    Y Mu, Y Cong (2019)
  17. Degradation of a mixture of 13 polycyclic aromatic hydrocarbons by commercial effective microorganisms.
    Paulina Książek-Trela, Damian Figura, Dominika Węzka, Ewa Szpyrka (2024) - Open life sciences
  18. Oral administration of probiotic spore ghosts for efficient attenuation of radiation-induced intestinal injury.
    Cuixia Zheng, Mengya Niu, Yueyue Kong, Xinxin Liu, Junxiu Li, Xunwei Gong, Xinyuan Ren, Chen Hong, Menghao Yin, Lei Wang (2024) - Journal of nanobiotechnology
  19. Bacillus coagulans SCC-19 maintains intestinal health in cadmium-exposed common carp (Cyprinus carpio L.) by strengthening the gut barriers, relieving oxidative stress and modulating the intestinal microflora.
    Xulu Chang, Meiru Kang, Yihao Shen, Lili Yun, Guokun Yang, Lei Zhu, Xiaolin Meng, Jianxin Zhang, Xi Su (2021) - Ecotoxicology and environmental safety
  20. Probiotic Efficacy in Aquaculture: The Role of Technospore® (Bacillus coagulans) in Improving Nile Tilapia (Oreochromis niloticus) Performance and Disease Resistance: a Study on Gut Health, Immunological Response, and Gene Expression.
    Amira A Omar, Mohamed S Gado, Hamada E Kandel, Foad A Farrag, Mustafa Shukry (2025) - Probiotics and antimicrobial proteins


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!